LobbyingGrand Pharmaceutical Group LTD Limited) lobbying by quarter
Grand Pharmaceutical Group LTD Limited)'s latest lobbying report covers Q1 2026, at $90K. The four quarters Q4 2025–Q3 2026 total $120K. Its first report covers Q4 2025; the issues it reports most are Foreign Relations and Health Issues.
Grand Pharmaceutical Group LTD Limited)
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $120K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $30K | 1 |
| Q1 2026 | $90K | 1 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Foreign relations$60K · 2 reports
- Health issues$60K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Treasury, Dept of2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Checkmate Government Relations | $120K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JAMES MILAM JOHNSON | Sp. Adv. to Dep. Sec., Treasury; Sp. Asst. to US House Majority Leader Steve Scalise; Exec. Asst. to Senior Advisor to President for Policy, White House; Confidential Asst., Office of Management & Budget; Legislative Aide, US Sen. Cindy Hyde-Smith | Q1 2026 |
| MUHAMMAD USMAN RAHIM | Special Asst. Office of the Executive Secretariat | Q1 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 06/12for Q1 | Checkmate Government Relations | $90K |
| 04/19for Q1 | Checkmate Government Relations | $90K |
| 02/13for Q4 2025 | Checkmate Government Relations | $30K |
| 01/30for Q4 2025 | Checkmate Government Relations | Under $5,000 |
| 01/27for Q4 2025 | Checkmate Government Relations | Under $5,000 |